tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

ELVN Stock Latest News

Enliven, Novartis drugs poised to lead in CML markets, says Clear Street
The FlyEnliven, Novartis drugs poised to lead in CML markets, says Clear Street
3d ago
NVS
ELVN
Enliven Therapeutics: Strong Buy Rating Backed by Promising Clinical Results and Robust Financial Position
PremiumRatings
Enliven Therapeutics: Strong Buy Rating Backed by Promising Clinical Results and Robust Financial Position
2M ago
ELVN
Enliven Therapeutics: Strong Financial Foundation and Promising ELVN-001 Development Justify Buy Rating
PremiumRatings
Enliven Therapeutics: Strong Financial Foundation and Promising ELVN-001 Development Justify Buy Rating
2M ago
ELVN
Enliven Therapeutics: Strong Financial Health and Promising CML Treatment Drive Buy Rating
PremiumRatings
Enliven Therapeutics: Strong Financial Health and Promising CML Treatment Drive Buy Rating
2M ago
ELVN
Enliven Therapeutics Reports Positive Trial Results and Strong Financials
PremiumCompany Announcements
Enliven Therapeutics Reports Positive Trial Results and Strong Financials
2M ago
ELVN
Enliven files automatic mixed securities shelf
PremiumThe FlyEnliven files automatic mixed securities shelf
2M ago
ELVN
Enliven reports Q2 EPS (49c) vs. (41c) last year
Premium
The Fly
Enliven reports Q2 EPS (49c) vs. (41c) last year
2M ago
ELVN
Enliven Therapeutics’ Promising Phase 1a/1b Study on ELVN-002 in HER2+ Cancers
Premium
Company Announcements
Enliven Therapeutics’ Promising Phase 1a/1b Study on ELVN-002 in HER2+ Cancers
3M ago
ELVN
Enliven Therapeutics’ Promising CML Treatment: A Study Update
PremiumCompany Announcements
Enliven Therapeutics’ Promising CML Treatment: A Study Update
3M ago
ELVN
Enliven Therapeutics’ Promising CML Study Update: What Investors Need to Know
PremiumCompany Announcements
Enliven Therapeutics’ Promising CML Study Update: What Investors Need to Know
3M ago
ELVN
Enliven Therapeutics Advances CML Treatment with ELVN-001 Study
PremiumCompany Announcements
Enliven Therapeutics Advances CML Treatment with ELVN-001 Study
4M ago
ELVN
Enliven price target raised to $48 from $40 at H.C. Wainwright
PremiumThe Fly
Enliven price target raised to $48 from $40 at H.C. Wainwright
4M ago
ELVN
Enliven Therapeutics’ Promising CML Study: A Potential Game-Changer?
PremiumCompany AnnouncementsEnliven Therapeutics’ Promising CML Study: A Potential Game-Changer?
4M ago
ELVN
Enliven Therapeutics Advances in HER2 Mutant Lung Cancer Study
Premium
Company Announcements
Enliven Therapeutics Advances in HER2 Mutant Lung Cancer Study
4M ago
ELVN
Enliven Therapeutics Appoints New Directors at Annual Meeting
Premium
Company Announcements
Enliven Therapeutics Appoints New Directors at Annual Meeting
4M ago
8K
ELVN
Short Report: Short interest in residential solar heats up again
PremiumThe Fly
Short Report: Short interest in residential solar heats up again
4M ago
DBI
GES
Enliven price target raised to $52 from $40 at Baird
PremiumThe Fly
Enliven price target raised to $52 from $40 at Baird
4M ago
ELVN
Enliven Therapeutics Announces Public Offering Agreement
PremiumCompany Announcements
Enliven Therapeutics Announces Public Offering Agreement
4M ago
8K
ELVN
Promising Potential of Enliven Therapeutics’ ELVN-001: Buy Rating Reiterated with Strong Efficacy, Safety, and Market Opportunity
PremiumRatings
Promising Potential of Enliven Therapeutics’ ELVN-001: Buy Rating Reiterated with Strong Efficacy, Safety, and Market Opportunity
4M ago
ELVN
Optimistic Buy Rating for Enliven Therapeutics Driven by Promising ELVN-001 Data and Strategic Growth Plans
PremiumRatingsOptimistic Buy Rating for Enliven Therapeutics Driven by Promising ELVN-001 Data and Strategic Growth Plans
4M ago
ELVN
Enliven assigned with a Buy at Goldman Sachs
Premium
The Fly
Enliven assigned with a Buy at Goldman Sachs
4M ago
ELVN
Enliven Therapeutics: Promising Phase 1 Data and Strong Financial Position Support Buy Rating
Premium
Ratings
Enliven Therapeutics: Promising Phase 1 Data and Strong Financial Position Support Buy Rating
4M ago
ELVN

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >